雖然這篇elafibranor pbc鄉民發文沒有被收入到精華區:在elafibranor pbc這個話題中,我們另外找到其它相關的精選爆讚文章
[爆卦]elafibranor pbc是什麼?優點缺點精華區懶人包
你可能也想看看
搜尋相關網站
-
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#1Elafibranor in PBC | Genfit
Elafibranor was granted Breakthrough Therapy designation by the FDA in April 2019 for the treatment of PBC in adults with inadequate response to UDCA, as well ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#2A randomized placebo-controlled trial of ... - Science Direct
Patients with primary biliary cholangitis (PBC) who have an incomplete response to ursodeoxycholic acid remain at risk of disease progression. We investigated ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#3A randomized placebo-controlled trial of elafibranor ... - PubMed
Background & aims: Patients with primary biliary cholangitis (PBC) who have an incomplete response to ursodeoxycholic acid remain at risk of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#4Study of Elafibranor in Patients With Primary ... - Clinical Trials
... oral administration of 80mg elafibranor on cholestasis (impairment of bile formation and/or bile accumulation) in patients with PBC and ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#5Ipsen and GENFIT enter into exclusive licensing agreement ...
... and delta agonist elafibranor in Primary Biliary Cholangitis (PBC) ... safety and efficacy of elafibranor in 150 people living with PBC ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#6A randomized placebo-controlled trial ... - Journal of Hepatology
Although PBC hyperlipidaemia has not been associated with increased risks of cardiovascular events, the activity profile of elafibranor on ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#7Elafibranor in Primary Biliary Cholangitis | Cedars-Sinai
Elafibranor in Primary Biliary Cholangitis study focuses on individuals who have been diagnosed with primary biliary cholangitis (PBC), a chronic liver ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#8Elafibranor safe, effective in patients with PBC - Healio
“These promising findings along with existing safety data derived from past clinical trials suggest elafibranor is a promising development ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#9Study of Elafibranor in Patients With Primary ... - Yale Medicine
Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) (ELATIVE). Study HIC#:2000030228. Last Updated:12/17/2021.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#10Elafibranor moves to Phase 3 Study called ELATIVE
Recent Posts · GSK Phase 3 trial for PBC itch now enrolling January 26, 2022 · Mirum – Phase 2 trial for PBC itch January 21, 2022 · Study shows ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#11GENFIT: new market research data highlight potential of
2021年2月22日 — The total PBC market is estimated to reach $1.5 billion annually in 2035, and elafibranor, if approved, could achieve $515 million in peak year ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#12Ipsen and GENFIT Enter Into Exclusive Licensing ... - BioSpace
2021年12月17日 — ... and delta agonist elafibranor in Primary Biliary Cholangitis (PBC) ... safety and efficacy of elafibranor in 150 people living with PBC ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#13Ipsen places €480m bet on Genfit's liver drug elafibranor -
Genfit is also in line for another €360 million if elafibranor reaches the market for PBC and hits its sales targets, and Ipsen as also ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#14Efficacy and Safety of Elafibranor in Patients with PBC - Health ...
Elafibranor is being developed by Genfit for the treatment of PBC, based on its pharmacological properties. This Phase 3 study is being conducted to evaluate ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#15While we wait for NASH data, Genfit reports positive ...
The 12-week phase II trial tested two doses of the dual PPARα/δ agonist elafibranor against a placebo in PBC patients that did not derive adequate benefit ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#16Genfit rises from the ashes of elafibranor | Evaluate
The deal validates Genfit's decision to press on with elafibranor in the new indication, primary biliary cholangitis (PBC), where the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#17Ipsen and GENFIT Enter Into Exclusive ... - Yahoo Finance
... and delta agonist elafibranor in Primary Biliary Cholangitis (PBC) ... and commercialize GENFIT's investigational treatment elafibranor, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#18A Study of Elafibranor in Patients With Primary Biliary ...
PBC is a chronic liver disease resulting from progressive destruction of the liver bile ducts. When the ducts are destroyed, bile (fluid made in your liver) ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#19Clinical Trial on Primary Biliary Cholangitis (PBC): Elafibranor ...
Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#20Clinical Trials - Mayo Foundation for Medical Education and ...
Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#21Genfit's elafibranor hits goal in phase 2 PBC trial | FierceBiotech
A phase 2 trial of Genfit's elafibranor in primary biliary cholangitis (PBC) has hit its primary endpoint. The readout sets Genfit up to ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#22Genfit - Clinical Trial for those with limited response to URSO
We are holding an investigational study in PBC for patients who have not ... study of the drug Elafibranor and its effect on PBC whilst taken with Urso.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#23Scant backlash from NASH crash as Genfit scores $539M-plus ...
Elafibranor, a first-in-class PPAR alpha and delta agonist, is expected to yield top-line phase III data from the PBC study called Elative ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#24Genfit NASH藥物三期試驗失敗股價狂跌65% - 環球生技
試驗結果中,elafibranor組別有19%的患者肝炎和肝細胞膨脹的情形獲得改善,且 ... Genfit表示,NASH和PBC是完全不同的疾病,因此elafibranor在NASH的 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#25Ipsen gets rights to failed Genfit NASH drug, now in Phase 3 ...
Elafibranor is currently in Phase 3 testing in primary biliary cholangitis (PBC), a chronic autoimmune disease that leads to inflammation ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#26A randomized placebo-controlled trial of elafibranor in patients ...
Background & Aims: Patients with primary biliary cholangitis (PBC) who have an ... Conclusion: In this randomized phase II trial, elafibranor was generally ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#27Research study for adults with primary biliary cholangitis (PBC)
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#28Genfit rockets on signing two deals in one day, now with Ipsen ...
... manufacture and commercialize Genfit's investigational treatment elafibranor, for people living with primary biliary cholangitis (PBC).
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#29Elafibranor Gets Breakthrough Therapy Designation for ...
The FDA has granted Breakthrough Therapy designation to elafibranor for the treatment of primary biliary cholangitis (PBC) in adults with ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#30Elafibranor - Genfit - AdisInsight
Primary biliary cirrhosis (PBC). The European Medicines Agency (EMA) and the US FDA, in July 2019, granted orphan drug designation to elafibranor for the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#31Genfit : des résultats positifs de Phase 2 avec elafibranor chez ...
Genfit : des résultats positifs de Phase 2 avec elafibranor chez des patients atteints de PBC publiés dans le Journal of Hepatology.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#32肝病疗法elafibranor获FDA突破性疗法认定即将进入3期临床
Elafibranor 是一款“first-in-class”PPARα/δ激动剂,在治疗PBC患者的2期临床试验中表现出积极疗效,它同时在3期临床试验中治疗非酒精性脂肪性 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#33Terns Pharmaceuticals拓臻生物與GENFIT簽署 ... - 美国商业资讯
兩家公司還將共同開發其他非酒精性肝炎(NASH)和原發性膽汁性膽管炎(PBC)領域的研發計畫,包括elafibranor(PPAR α/δ 和拓臻自身管線裡 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#34Genfit - AP News
FDA grants elafibranor Breakthrough Therapy Designation, based on Phase 2 data, for treatment of PBC (Primary Biliary Cholangitis) in adults ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#35ICTRP Search Portal
Public title: Phase 2 Efficacy & Safety Study of Elafibranor in patients with PBC. Scientific title: A Multicenter, Double-Blind, Randomized, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#36GENFIT : dans la PBC, elafibranor a du potentiel - Capital.fr
GENFIT : dans la PBC, elafibranor a du potentiel ... (AOF) - Genfit a annoncé que de nouvelles études de marché mettaient en évidence le potentiel ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#37Bryan, Garnier & Co acts as Joint Bookrunner to Genfit on its ...
Other clinical programs include Phase III-ready elafibranor in PBC (Primary Biliary Cholangitis) and Phase II Nitazoxanide in NASH-induced fibrosis.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#38A Double‐blind, Randomized, Placebo‐Controlled Study and ...
Primary Biliary Cholangitis (PBC) is a chronic liver disease resulting from progressive destruction of the liver bile ducts. Elafibranor is considered to be ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#39FDA Grants Genfit Breakthrough Designation for PBC Disease
Genfit's elafibranor earned the FDA's breakthrough therapy designation for treating primary biliary cholangitis (PBC), a rare autoimmune ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#40GENFIT completes enrolment in Phase lla trial of elafibranor ...
“This attribute, along with what PPAR agonists have demonstrated on ALP reduction, provides a strong rationale for elafibranor in PBC.” Top line ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#41After NASH Failures, Genfit Restructures and Cuts Staff by 40 ...
The company will now focus on two priority areas. The first is the Phase III ELATIVE trial of elafibranor in primary biliary cholangitis (PBC), ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#42FR - EU Clinical Trials Register
... Phase 2 Study to Evaluate the Efficacy and Safety of Elafibranor ... Phase 2 Efficacy & Safety Study of Elafibranor in patients with PBC ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#43Study of Elafibranor in Patients With Primary Biliary ...
... the effect of daily oral administration of 80mg elafibranor on cholestasis (impairment of bile formation and/or bile accumulation) in patients with PBC ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#44GNFT.PA - Genfit SA Key Developments | Reuters
ELAFIBRANOR IN PBC (ELATIVETM PHASE 3): TIMELINE FOR POTENTIAL FDA FILING NOW ESTIMATED IN H2 2023, BASED ON SUCCESSFUL PHASE 3 TRIAL OUTCOME.NEW CLINICAL DATA ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#45Green Light for Genfit to Tackle another Liver Disease
... Phase II trials for Primary Biliary Cholangitis (PBC). The drug tested will be Elafibranor, Genfit's lead candidate seeking to unlock the NASH market.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#46拓臻生物合作伙伴GENFIT宣布Elafibranor获FDA和EMA治疗原 ...
原发性胆汁性胆管炎(PBC)是以慢性进行性胆汁淤积为主要特征的自身免疫性肝病,由胆管损伤导致肝组织瘢痕化,称为肝硬化。该疾病病因尚不明确,多见于中年妇女,许多患者 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#47GENFIT : dans la PBC, elafibranor a du potentiel - 23/02/2021 ...
(AOF) - Genfit a annoncé que de nouvelles études de marché mettaient en évidence le potentiel d'elafibranor dans la Cholangite Biliaire ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#48拓臻生物与GENFIT签署Elafibranor大中华区独家产品授权及 ...
两家公司还将共同开发其他非酒精性肝炎(NASH)和原发性胆汁性胆管炎(PBC)领域的研发项目,包括elafibranor(PPAR α/δ双重激动剂)和拓臻自身管线里 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#49Genfit scraps phase 3 trial of experimental NASH drug - PMLiVE
... experimental nonalcoholic steatohepatitis (NASH) drug elafibranor ... development of elafibranor in primary biliary cholangitis (PBC) ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#50A Study of Elafibranor in Patients With Primary Biliary ...
Keywords. Primary Biliary Cirrhosis Primary Biliary Cholangitis PBC Elafibranor Cholangitis Liver Cirrhosis, Biliary Elafibranor 80mg ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#51GENFIT: Major Milestone achieved with full recruitment of the ...
Final patient randomized in a Phase 2a clinical trial evaluating efficacy and safety of elafibranor in PBC (Primary Biliary Cholangitis), ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#52Statins, Fibrates, and Other Peroxisome Proliferator-Activated ...
Abstract: Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) ... Novel PPAR agonists being developed for use in PBC are elafibranor, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#53GFT505B-319-1 PBC | University of Utah Health
To evaluate the effect of elafibranor (80 mg/day) on cholestasis as defined by the primary endpoint over 52 weeks of treatment compared to placebo.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#54Álvaro Díaz-González on Twitter: "Elafibranor (EF) in patients ...
Elafibranor (EF) in patients with #PBC Phase II trial (EF80mg EF120mg Placebo) ✓67% patients (80mg) & 79% (120mg) ALP <1.67 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#55Primary Biliary Cholangitis clinical trials at UC Davis
A Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC). “Volunteer for research and contribute to discoveries that may ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#56IPSEN/GENFIT | Business Wire - Via Ritzau
... GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, ... safety and efficacy of elafibranor in 150 people living with PBC ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#57Genfit's elafibranor shows promising action in chronic liver ...
... Phase 2 trial of elafibranor in patients with Primary Biliary Cholangitis (PBC) with incomplete response to ursodeoxycholic acid (UDCA), ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#58A randomized placebo-controlled trial of elafibranor ... - X-MOL
BACKGROUND AND AIM Patients with primary biliary cholangitis (PBC) who have an incomplete response to ursodeoxycholic acid remain at risk of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#59WO2017167935A1 - Methods of treatment of cholestatic ...
... for treating cholestatic diseases, and more specifically PBC and/or PSC. ... Prior art keywords: elafibranor: pbc: disease: cholestatic: patients ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#60Genfit en forte hausse après des résultats positifs pour ...
... positifs dans l'étude de phase II de son produit elafibranor dans ... évaluant elafibranor dans la Cholangite Biliaire Primitive (PBC), ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#61End of the line for Genfit's experimental NASH drug
Development of elafibranor will be discontinued for NASH, with the company now focusing on its future as a treatment for PBC - News ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#62罕见肝病新药!PPARα/δ激动剂elafibranor获孤儿药资格 - 生物谷
近日,该公司宣布,美国食品和药物管理局(FDA)和欧洲药品管理局(EMA)已授予其先导候选药物PPARα/δ双重激动剂elafibranor治疗原发性胆汁性胆管炎(PBC ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#63Terns Pharmaceuticals拓臻生物與GENFIT簽署 ... - 中央社
兩家公司還將共同開發其他非酒精性肝炎(NASH)和原發性膽汁性膽管炎(PBC)領域的研發計畫,包括elafibranor(PPAR α/δ 和拓臻自身管線裡 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#64FDA grants breakthrough status to Genfit's elafibranor
The FDA has granted breakthrough therapy designation to Genfit's elafibranor to treat adults with primary biliary cholangitis (PBC).
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#65ELAFIBRANOR AMAZING RESULTS IN PBC - nash biotechs
GENFIT has published the first results of its Elafibranor efficacy and safety clinical trial for patients with Primary Biliary Cholangitis (PBC) and an ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#66Elafibranor demonstrates significant anticholestatic effects in ...
The Phase 2 study involved 45 individuals with PBC without cirrhosis who had not responded adequately to UDCA treatment (defined as an ALP >1.67 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#67δ激動劑elafibranor獲孤兒藥資格,治療原發性膽汁性膽管炎(PBC)
2019年07月30日訊/. 生物谷. BIOON/ --Genfit是一家處於後期臨牀階段的生物製藥公司,致力於發現和開發創新的治療和.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#68Clinical Pharmacy Services
Elafibranor 80 mg or 120 mg orally once daily or placebo for 52 weeks ... NAS=NAFLD activity score, PBC=primary biliary cholangitis, PPAR=peroxisome ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#69Clinical Updates in Primary Biliary Cholangitis - Xia & He ...
Primary biliary cholangitis (PBC), formerly known as primary biliary ... efficacy and safety of elafibranor after 12 weeks of treatment in patients with PBC ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#70Combined obeticholic acid and elafibranor treatment ... - Nature
Obeticholic acid (OCA) and elafibranor (ELA) are selective and potent ... UDCA for the treatment of primary biliary cholangitis (PBC).
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#71Elafibranor – Medicines – SPS - Specialist Pharmacy Service
Primary biliary cholangitis (PBC) in adults with ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#722182-public-summary-opinion-orphan-designation-elafibranor ...
2019年9月13日 — Elafibranor for the treatment of primary biliary cholangitis. On 25 July 2019, orphan designation EU/3/19/2182 was granted by the European ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#73pathophysiology and management of primary biliary cholangitis
Summary Background Primary biliary cholangitis (PBC), an immune-mediated disease characterised by destruction of intrahepatic bile ducts, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#74Ipsen Presents Strong Full-Year 2021 Results and Enters Into ...
... Ipsen announced an exclusive licensing agreement for elafibranor, which is in Phase III development in primary biliary cholangitis (PBC) ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#75trực tiếp bóng đá cúp fa
5 小時前 — Vào tháng 4 năm 2019, elafibranor, được sử dụng để điều trị cho bệnh nhân người lớn mắc PBC, đã nhận được chỉ định liệu pháp đột phá do FDA ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#76Liver Disease News
Canadian patients with the autoimmune liver disease primary biliary cholangitis (PBC) saw the first approval of a new drug for ... Read more.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#77Liver Immunology: Principles and Practice - 第 347 頁 - Google 圖書結果
Novel PPAR agonists being developed for use in PBC include elafibranor, a PPARα/δ agonist, and seladelpar, a PPARδ agonist. In a phase 2b, 12-week trial of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#78Primary Biliary Cholangitis, An Issue of Clinics in Liver ...
... 41 patients with UDCA nonresponsive PBC who were given the drug was stopped ... with PBC are underway (NCT02955602 and NCT03301506) Elafibranor (GFT505; ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#79Can Intercept Make it to the Finishing Line in NASH? - Avise ...
... financial year 2020 in PBC, where it was approved by the FDA in 2016. ... In July 2020, Genfit's elafibranor was unable to achieve the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#80Elafibranor | ≥99%(HPLC) | Selleck | PPAR agonist
It improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation. Elafibranor Chemical Structure. CAS No. 923978-27-2. Size ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#81Elafibranor (GFT505, CAS Number: 923978-27-2) - Cayman ...
Elafibranor is an agonist of the peroxisome proliferator-activated receptors (PPAR) α and δ. It increases HDL secretion and expression of the lipid-related ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#82Liver Diseases: A Multidisciplinary Textbook
... elafibranor, a dual PPARα/δ-agonist, are under way. Budesonide is a highly effective steroid, the first that was used as a second-line treatment for PBC ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#83The Liver: Biology and Pathobiology - Google 圖書結果
UDCA [53] and fibrates may be considered a second‐line treatment in PBC [54]. ... Another promising PPARα/δ dual agonist, elafibranor, with beneficial ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#84Diseases of the Liver and Biliary Tree - 第 130 頁 - Google 圖書結果
Other strategies include: a dual PPAR α/δ-agonist (elafibranor), ... 8.2.6 Risk Stratification PBC, even when treated, remains a progressive disease ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#85Mechanisms of Chronic Liver Diseases: Identifying New ...
We do acknowledge that the clinical significance of ALP in PBC and PSC is ... Seladelpar is a selective PPAR-δ agonist (34), while Elafibranor is PPARα/δ.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#86Cellular and Molecular Mechanisms Underlying the ...
... Selonsertib (GS-4997) Obeticholic acid Elafibranor Tropifexor Cilofexor ... is already approved for the treatment of primary biliary cholangitis (PBC).
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#87Elafibranor - Wikipedia
Elafibranor is an experimental medication that is being studied and developed by Genfit for the treatment of cardiometabolic diseases including diabetes, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?>
elafibranor 在 コバにゃんチャンネル Youtube 的最佳貼文
elafibranor 在 大象中醫 Youtube 的最佳貼文
elafibranor 在 大象中醫 Youtube 的最佳解答